Latest News

InnoCare Pharma has initiated a global trial for soficitinib, targeting prurigo nodularis, aiming to enhance treatment options for this chronic skin condition.

Alpha-9 Oncology's A9-3408 trial targets MC1R in advanced melanoma, offering a novel radiotherapeutic approach beyond traditional treatments.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of December.

Cosmo Pharmaceuticals reveals promising phase 3 results for clascoterone 5% solution, showing significant hair growth improvement in alopecia.

Tori Spelling and Stella McDermott share their journey with eczema, promoting the Free to Be Me campaign and discussing innovative treatments like roflumilast.

At the Horizons in Advanced Practice meeting, Omar Noor, MD, led NP and PA attendees through 3 complex cases of atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria.

Arash Mostaghimi, MD, MPH, FAAD, and experts discuss evolving treatment standards for alopecia areata, focusing on JAK inhibitors, patient-centered care, and future therapeutic innovations.

Discover how a proprietary extract from saw palmetto promotes hair growth and reduces thinning in adults, offering a safe alternative to traditional treatments.

The study provides new evidence beyond previously established associations with breast, ovarian, and uterine cancers.

This review of the latest dermatologic studies includes a new instrument to measure QoL in pediatric alopecia, BTX-A in patients with recessive dystrophic epidermolysis bullosa, eosinophilic pustular folliculitis in children, and more.

However, over half of the patients reported experiencing psychological symptoms such as mood changes and depression during treatment.

Citius Oncology’s IL-2 receptor–directed fusion protein offers rapid responses and pruritus improvement for relapsed or refractory stage I–III CTCL.

Participants agreed that HS is rarely controlled with monotherapy and often requires coordinated multimodal care.